Insilico's AI-designed cancer drug ISM6331 reaches first human data: ESMO oral session to report Phase 1 results

A small molecule designed by generative AI has reached the point where its first human data become public: the Phase 1 abstract for Insilico Medicine's ISM6331 is posted on the 2026 European Society for Medical Oncology (ESMO) website, with detailed data set for a Rapid Oral session in Madrid on October 25. Public progress on the molecule had previously stopped at preclinical candidate nomination and trial start: it was nominated as a preclinical candidate in June 2023 and entered a global multicenter Phase 1 study in January 2025. The milestone rests on the session itself: abstract number 997, presented by Melina E. Marmarelis of the Abramson Cancer Center at the University of Pennsylvania, in the 08:57 to 09:02 CET slot on October 25.

ISM6331 is an oral pan-TEAD inhibitor aimed at TEAD transcription factors downstream of the Hippo pathway, studied in patients with mesothelioma or other advanced solid tumors. TEAD transcription factors participate in signaling downstream of the Hippo pathway, which helps regulate cell growth and tissue maintenance; dysregulation of this network can contribute to cancer biology, giving a rationale for investigating TEAD inhibition in selected tumors. The ongoing multicenter, open-label Phase 1 study evaluates safety, tolerability, pharmacokinetics and preliminary antitumor activity, with objectives including dose-limiting toxicities and determination of a recommended Phase 2 dose.

The molecule's design and optimization were supported by Insilico's generative chemistry engine Chemistry42, and the program combines computational molecular design with laboratory evaluation and clinical development. The program's progression shows that an AI-designed candidate can move into human testing, while the evidence needed to establish clinical benefit remains a separate question for clinical investigation. The U.S. FDA has granted Orphan Drug Designation for mesothelioma and Fast Track Designation for adult patients with previously treated, unresectable malignant pleural mesothelioma; these designations support development but do not establish clinical efficacy or constitute marketing approval.

The report covers the session schedule, molecular mechanism background and trial design released by Insilico Medicine: the Phase 1 study is multicenter and open-label, evaluating safety, tolerability, pharmacokinetics and preliminary antitumor activity, including dose-limiting toxicities and a recommended Phase 2 dose. It is intended for researchers and engineers following AI-assisted drug discovery and early oncology clinical work.

Safety and preliminary antitumor activity data are not yet public and will come in the ESMO presentation and a subsequent announcement. FDA Orphan Drug and Fast Track designations support development but do not establish clinical efficacy or constitute marketing approval. An AI-designed candidate entering human testing and establishing clinical benefit are separate questions.